Potential role of montelukast on some physiological parameters in lab animals

The probable impact of montelukast, an LTRA selective in action, on various physiological parameters in model animals is determined in this study. Montelukast, which is primarily applied in the treatment of asthma and allergic rhinitis, is effective by inhibiting the activity of cysteinyl leukotriene type-1 (CysLT1) receptors and hence preventing inflammatory mediators like LTC4, LTD4, and LTE4 from having their action. Following critical analysis of preclinical research, this project describes the effects of montelukast on respiratory function, neuroinflammation, cardiovascular disease, and mechanisms of oxidative stress. Experiments demonstrate that montelukast inhibits airway hyperresponsiveness potently, inhibits eosinophilic infiltration, and reduces systemic inflammation through pro-inflammatory cytokine regulation of IL-4, IL-5, and IL-13. In addition, its neuroprotective activity-induced by inhibition of microglial activation and reduction of oxidative stress-provides therapeutic promise in neurodegenerative disease. The drug also had an antioxidant action via augmentation of superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzyme activities. Although of utility, unwarranted neuropsychiatric adverse effects of ill use in a few research studies are depression and anxiety, and limited clinical application would be valid. This research suggests the widespread therapeutic value of montelukast beyond its primary indication, and its therapeutic use in inflammatory, neurological, and cardiovascular conditions is worth studying.